Skip to main content

Table 2 Analysis of overlapping LXR- and PPARG-responsive genes

From: Distinct gene regulatory programs define the inhibitory effects of liver X receptors and PPARG on cancer cell proliferation

  Overlap 24 h (%) Concordant 24 h Discordant 24 h Percentage concordant 24 h Overlap 48 h (%) Concordant 24 h Discordant 24 h Percentage concordant 48 h
GW3965 (fc ±2) 32 (25.8 %) 29 3 90.6 % 203 (18.2 %) 119 84 58.6 %
T0901317 (fc ±2) 9 (15.5 %) 8 1 88.9 % 189 (16.9 %) 70 119 37.0 %
GW3965 (fc ±1.5) 119 (38.9 %) 100 19 84.0 % 790 (35.1 %) 381 409 48.2 %
T0901317 (fc ±1.5) 60 (35.1 %) 41 19 68.3 % 775 (32.1 %) 222 553 28.6 %
  1. The overlap between LXR-responsive genes (from GW3965 and T0901317 treatments) with PPARG-responsive genes (from rosiglitazone treatment) is shown at both 24 and 48 h. The number and percentage of total responsive genes is shown. The number of genes and percentages that show concordant and opposing changes in differential expression across all drug comparisons is also given. Hypergeometric tests of gene overlaps for both drug comparisons and time points were highly significant (p < 1e-16)